MK-5684 vs. Abiraterone or Enzalutamide in prostate cancer patients

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy

Disease Types: Prostate

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy

For More Information:

https://clinicaltrials.gov/study/NCT06136624?term=Opevesostat&rank=7